Gonadotropin releasing hormone agonist triggering for in vitro maturation cycles. (27th May 2022)

• Record Type: Journal Article
• Authors: Hershko Klement, Anat; Navve, Daniella; Ghetler, Yehudith; Wiser, Amir; Shavit, Tal; Weitzner, Omer; Shulman, Adrian
• Is Part Of: Human fertility. Volume 25:Number 3(2022)
• Page Start: 516
• Page End: 521
• Publication Date: 2022-05-27
• Subjects: In vitro oocyte maturation techniques -- gonadotropin-releasing hormone -- in vitro fertilisation -- ovulation; Fertility, Human -- Periodicals; Infertility -- Periodicals; 616.692
• DOI: 10.1080/14647273.2020.1858511
• Languages: English
• ISSNs: 1464-7273

Abstract

Abstract: The objective was to evaluate the outcomes of in vitro maturation (IVM) cycles using gonadotropin releasing hormone agonist (GnRH-ag) triggering. A retrospective cohort of IVM cycles from January 2015 to December 2019 in a single university-affiliated centre was examined. Main outcome measures were: (i) IVM maturation rate; and (ii) IVM maturation result. Secondary outcome measures were: (i) metaphase II (MII) rate on the day of egg retrieval; (ii) final MII maturation rate; and (iii) pregnancy rates. A total of 98 IVM cycles were performed during the study period: 50 (51%) were triggered with GnRH-ag (17 received FSH priming and 33 did not) and 48 cycles (49%) were triggered by hCG (37 with FSH priming and 11 without). A significant ( p = 0.01) difference was noticed in maturation rate on egg retrieval day, in favour of the GnRH-ag group, although not in the final maturation rate achieved. Pregnancy rates were comparable between treatment sub-groups. GnRH-ag triggering in IVM cycles is an optional triggering mode and can be considered an acceptable option, especially when fertility preservation is a concern. GnRH agonists resulted in higher maturation rate on day of oocyte retrieval, but no difference in the total maturation rate.